Use of ARNI in HFpEF patients reduces NT-proBNP levels

Use of ARNI in HFpEF patients reduces NTproBNP levels
3' education - Apr. 8, 2020 - Jonathan Cunningham, MD
  • Overview

    ACC 2020 Jonathan Cunningham shares three major findings from a subanalysis of the PARAGON-HF trial in HFpEF patients.

  • Educational information

    This video was recorded during the virtual congress of the American College of Cardiology (ACC) 2020.

  • Faculty

    Dr. Jonathan W. Cunningham, Brigham and Women's Hospital, Boston, MA, USA.

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

    Read our summary of this analysis

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free